Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations
MedComm · 2025-06 · 6 (6)
DOI: 10.1002/mco2.70231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 31.05.2025. Verfasst von Tianying Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine Guangdong Provincial Key Laboratory of Precision Medical Diagnostics Guangdong Engineering and Technology Research …. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that expand aberrantly in cancer and exhibit potent immunosuppressive properties. They contribute to tumor progression through both immunological and nonimmunological mechanisms. Immunologically, MDSCs suppress antitumor responses by inhibiting effector cells such as T cells and NK cells, facilitating immune evasion. Nonimmunologically, they promote tumor growth and metastasis through processes such as the epithelial‒mesenchymal transition, angiogenesis, and premetastatic niche formation. MDSC accumulation is closely linked to accelerated tumor progression, including resistance to both immunotherapies and conventional treatments, making these cells critical therapeutic targets. Clinical studies have demonstrated the potential of MDSC‐targeted strategies to improve treatment efficacy. However, challenges remain in achieving specificity and effectiveness in MDSC‐targeted therapies, emphasizing the need for a deeper understanding of their biology. This review summarizes the origin, classification, and biological characteristics of MDSCs, their dual roles in tumor progression, and their clinical significance. We also discuss recent advances in clinical and preclinical studies, including both traditional targeted therapies and emerging innovative strategies. By integrating current findings, we aim to provide a comprehensive perspective on the role of MDSCs in cancer and valuable insights for advancing cancer treatment and drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine Guangdong Provincial Key Laboratory of Precision Medical Diagnostics Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors Guangdong Provincial Key Labora…
- Department of Thoracic Surgery Nanfang Hospital Southern Medical University Guangzhou China.
- The Laboratory of Endocrinology and Metabolism Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hu, T., Zhai, J., Yang, Z., Peng, J., Wang, C., Liu, X., Li, Y., Yao, J., Chen, F., Li, H., An, T., Liu, Z., & Wang, H. (2025). Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations. MedComm, 6(6). https://doi.org/10.1002/mco2.70231
Vancouver
Hu T, Zhai J, Yang Z, Peng J, Wang C, Liu X, et al. Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations. MedComm. 2025;6(6). doi:10.1002/mco2.70231
BibTeX
@article{Hu2025,
author = {Hu, Tianying and Zhai, Jianxue and Yang, Zhanda and Peng, Jiajia and Wang, Chuxuan and Liu, Xinyao and Li, Yawen and Yao, Jiaqi and Chen, Fengxi and Li, Haixia and An, Taixue and Liu, Zongcai and Wang, Haifang},
title = {Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations},
journal = {MedComm},
year = {2025},
volume = {6},
number = {6},
doi = {10.1002/mco2.70231}
}
EUVIMED